The FDA approved the first mRNA flu vaccine for use in older adults on Aug. 14 [3].
This development marks a shift in how public health officials combat a virus that causes hundreds of thousands of deaths each year [1]. Because the influenza virus replicates quickly and evolves, traditional vaccine methods often struggle to keep pace with shifting strains.
Influenza is a worldwide respiratory virus that circulates globally each year [1, 2]. The virus typically peaks during the winter months in each hemisphere [2]. "Winter is coming, and with the cold weather comes respiratory viral infections, including influenza," MSN Health said.
The virus operates by replicating within airway cells, which provokes an immune response. While this response is intended to clear the infection, it can damage lung tissue [1, 4]. In severe cases, the infection can spread to other organs, leading to complications such as pneumonia, and organ failure [1, 3, 4].
Health experts note that the flu often arrives without warning, like an unwelcome guest that promises to leave soon, MSN Health said. While vaccines are generally effective [2], the severity of the illness varies by individual. Listening to the body's symptoms is critical to preventing the most severe outcomes [3].
The introduction of mRNA technology for influenza aims to provide a more precise and rapid response to the virus. By using messenger RNA, the vaccine instructs cells to produce a protein that triggers an immune response without using a live or weakened virus.
“The FDA approved the first mRNA flu vaccine for use in older adults.”
The shift toward mRNA technology for influenza suggests a move toward more agile vaccine production. Unlike traditional egg-based methods, mRNA platforms can be updated more quickly to match the specific strains circulating in a given year, potentially increasing the efficacy of seasonal shots for high-risk populations like the elderly.
